A5024085514- Antibiotic Use and Resistance
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Antibiotics Pharmacokinetics and Efficacy
- Antifungal resistance and susceptibility
- Urinary Tract Infections Management
- Tuberculosis Research and Epidemiology
- Sepsis Diagnosis and Treatment
- Pneumonia and Respiratory Infections
- Antibiotic Resistance in Bacteria
- Clostridium difficile and Clostridium perfringens research
- Blood disorders and treatments
- Mycobacterium research and diagnosis
- Abdominal Trauma and Injuries
- Infectious Diseases and Tuberculosis
- Dental Research and COVID-19
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Fungal Infections and Studies
- Patient Satisfaction in Healthcare
- Congenital Anomalies and Fetal Surgery
- Bacterial Infections and Vaccines
- Toxin Mechanisms and Immunotoxins
- Medical and Biological Ozone Research
- Spinal Dysraphism and Malformations
- Travel-related health issues
Brigham and Women's Hospital
2018-2025
Northeastern University
2017-2025
Harvard University
2024
Engineering Associates (United States)
2016
Midwestern University
2016
University of New Mexico Hospital
2015
University of New Mexico
2015
Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly those barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed provide further multicenter real-world evidence on use a sequential therapy for BSI. One hundred fifteen received BSI, defined any positive blood culture diagnosed infective endocarditis, from 13 centers geographically spread...
Omadacycline is an aminomethylcycline antimicrobial approved by the US Food and Drug Administration in 2018 for community-acquired bacterial pneumonia acute skin structure infections. It has vitro activity against nontuberculous mycobacteria, including Mycobacterium abscessus complex, but clinical data this indication are lacking.Omadacycline use was reviewed at 804-bed academic medical center. Patients were included if they received omadacycline culture-proven M disease 2019.Four patients...
Abstract Background Dalbavancin has been used off-label to treat invasive bacterial infections in vulnerable populations like people who use drugs (PWUD) because of its broad gram-positive coverage and unique pharmacological properties. This retrospective, multisite study examined clinical outcomes at 90 days PWUD versus non-PWUD after secondary treatment with dalbavancin for bacteremia, endocarditis, osteomyelitis, septic arthritis, epidural abscesses. Methods Patients 3 teaching hospitals...
ABSTRACT Tobramycin dosing in patients with cystic fibrosis (CF) is challenged by its high pharmacokinetic (PK) variability and narrow therapeutic window. Doses are typically individualized using two-sample log-linear regression (LLR) to quantify the area under concentration-time curve (AUC). Bayesian model-informed precision (MIPD) may allow dose individualization fewer samples; however, relative performance of these methods unknown. This single-center retrospective analysis included adult...
ABSTRACT Neoscytalidium dimidiatum is a mold known to cause onychomycosis and dermatomycosis; however, it an extremely rare of systemic infection. We report case pulmonary infection with in immunocompromised patient discuss vitro susceptibility data from this previous literature.
Sepsis guidelines recommend daily review to de-escalate or stop antibiotics in appropriate patients. This randomized, controlled trial evaluated an opt-out protocol decrease unnecessary patients with suspected sepsis.We non-intensive care adults on broad-spectrum despite negative blood cultures at 10 US hospitals from September 2018 through May 2020. A 23-item safety check excluded ongoing signs of systemic infection, concerning inadequate microbiologic data, high-risk conditions. Eligible...
Abstract Background Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. Methods was a 14-center retrospective cohort adult inpatients ≥24 hours MDR P. aeruginosa infections. Patients were defined as if they had history previous solid organ transplant (SOT), disease that increased susceptibility to infection, or...
Aim: To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under concentration-time curve (AUC) estimations. Methods: Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving intravenous vancomycin. Vancomycin AUC monitoring was compared using or PK equations. The primary endpoint time taken estimate determine regimen adjustments. Secondary endpoints included percentage...
Abstract Objectives: To determine how pharmacists with formal antimicrobial stewardship program (ASP) responsibilities prioritize their time and without contribute to ASP activities. Design: A nationwide survey. Respondents: Members of the American College Clinical Pharmacy who subscribe following practice research network e-mail listservs: infectious diseases, adult medicine, cardiology, critical care, hematology–oncology, immunology transplantation, pediatrics. Methods: survey was...
OBJECTIVE To evaluate the effect of healthcare worker (HCW) influenza vaccination on incidence nosocomial DESIGN Retrospective cross-sectional study SETTING A 550-bed tertiary-care academic medical center METHODS All admitted patients with a direct fluorescent antibody (DFA) or polymerase chain reaction (PCR) assay positive for ordered between October 1 and May 31 from 2010 to 2015 were eligible inclusion. Nosocomial was defined as test collected ≥48 hours after admission in without...
Current vancomycin monitoring guidelines recommend 24-hour area under the concentration-time curve (AUC) to minimum inhibitory concentration ratios for patients with serious methicillin-resistant
Current vancomycin guidelines recommend early and frequent area-under-the-curve monitoring in patients with obesity. Vancomycin's volume of distribution is likely altered obesity, which may result lower serum concentrations initially but lead to accumulation continued use. The objective this study was evaluate the incidence obesity identify potential factors associated accumulation.This a single-center, retrospective, observational at tertiary academic medical center. Adult body mass index...
Chronic granulomatous disease (CGD) is a primary immunodeficiency syndrome that results in increased risk for bacterial and fungal infections, as well inflammatory/autoimmune complications. While CGD historically has been associated with early death childhood, the life expectancy morbidity of patients have greatly improved. Many now survive into adulthood, data on adult cohorts published. However, reports pregnancy management, complications, outcomes are sparse. In addition, management...
Abstract Background Dalbavancin has been used off label to treat invasive gram-positive bacterial infections due its long half-life, eliminating the need for term IV access and prolonged hospital stays. It is a particularly useful option in vulnerable populations such as people who use drugs (PWUD) face unique challenges with antibiotics. This large, retrospective, multi-site study examined outcomes at 90 days PWUD vs non-PWUD after treatment dalbavancin bacteremia, endocarditis,...
Abstract Background Dalbavancin (DAL) received Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin structure infections (ABSSSI) caused by Gram-positive organisms including Methicillin-resistant Staphylococcus aureus (MRSA). Due to its unique activity dosing schedule, use in non-FDA approved indications has been increasing. We evaluated clinical safety outcomes patients treated with DAL various infections. Methods A multicenter, retrospective observational...
Abstract Background Staphylococcus aureus bacteremia is a significant cause of mortality. Penicillin (PCN) may have role in the treatment penicillin-susceptible (PSSA) as it has narrower spectrum activity than cefazolin and better tolerated antistaphylococcal penicillins (ASPs). The aim this study to evaluate safety effectiveness PCN versus or ASPs PSSA bacteremia. Methods This single-center, retrospective at tertiary academic medical center. All patients with blood culture from January 1,...
Abstract Introduction It has been estimated that nearly 50% of antibiotics are inappropriately prescribed in the outpatient setting. Despite much discussion surrounding importance reducing these occurrences, literature is limited describing antibiotic prescribing patterns for urinary tract infections (UTIs) primary care Objectives The objective this study was to evaluate if UTIs settings concordantly with evidence‐based guidelines. Methods This retrospective cohort reviewed female patients...
Abstract Background The Infectious Diseases Society of America recommends serial safety lab monitoring during outpatient parenteral antimicrobial therapy (OPAT) to assess treatment response and prevent adverse events. However, these recommendations do not address the profile specific agents or ideal frequency monitoring. Previous studies, using cohorts fewer than 300 patients, report event rates less 5% with cefazolin. It is possible that for patients on cefazolin monotherapy may represent...
Abstract Background An estimated 25% of U.S. nursing home residents may have an antibiotic resistant infection. Antibiotic resistance is primarily driven by use, thus, increasing our understanding trends in use within homes needed to address this public health threat. Our study examined changes prescriptions among using claims data from January 2018 through December 2020. Methods Linked files Medicare Part D and the Minimum Dataset 3.0 covering years 2018-2020 were used describe via...